BRPI0808655A2 - anticorpos monoclonais de he4 e métodos para a sua utilização. - Google Patents

anticorpos monoclonais de he4 e métodos para a sua utilização.

Info

Publication number
BRPI0808655A2
BRPI0808655A2 BRPI0808655A BRPI0808655A BRPI0808655A2 BR PI0808655 A2 BRPI0808655 A2 BR PI0808655A2 BR PI0808655 A BRPI0808655 A BR PI0808655A BR PI0808655 A BRPI0808655 A BR PI0808655A BR PI0808655 A2 BRPI0808655 A2 BR PI0808655A2
Authority
BR
Brazil
Prior art keywords
methods
monoclonal antibodies
monoclonal
antibodies
Prior art date
Application number
BRPI0808655A
Other languages
English (en)
Inventor
W Groelke John
L Cheek Robert
J Fischer Timothy
Original Assignee
Tripath Imaging Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tripath Imaging Inc filed Critical Tripath Imaging Inc
Publication of BRPI0808655A2 publication Critical patent/BRPI0808655A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57449—Specifically defined cancers of ovaries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Gynecology & Obstetrics (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
BRPI0808655A 2007-03-09 2008-03-07 anticorpos monoclonais de he4 e métodos para a sua utilização. BRPI0808655A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90612607P 2007-03-09 2007-03-09
PCT/US2008/056132 WO2008112514A1 (en) 2007-03-09 2008-03-07 He4 monoclonal antibodies and methods for their use

Publications (1)

Publication Number Publication Date
BRPI0808655A2 true BRPI0808655A2 (pt) 2018-10-23

Family

ID=39567774

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0808655A BRPI0808655A2 (pt) 2007-03-09 2008-03-07 anticorpos monoclonais de he4 e métodos para a sua utilização.

Country Status (10)

Country Link
US (2) US7846692B2 (pt)
EP (1) EP2121761A1 (pt)
JP (1) JP2010520768A (pt)
KR (1) KR20100015438A (pt)
CN (1) CN101802014A (pt)
AU (1) AU2008226587A1 (pt)
BR (1) BRPI0808655A2 (pt)
CA (1) CA2679696A1 (pt)
MX (1) MX2009009450A (pt)
WO (1) WO2008112514A1 (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002258518A1 (en) * 2001-03-14 2002-09-24 Millennium Pharmaceuticals, Inc. Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer
US7270960B2 (en) * 2001-08-29 2007-09-18 Pacific Northwest Research Institute Diagnosis of ovarian carcinomas
WO2006119155A2 (en) * 2005-05-02 2006-11-09 The Brigham And Women's Hospital, Inc. Diagnostic serum antibody profiling
ATE554389T1 (de) * 2007-03-23 2012-05-15 Hoffmann La Roche Apex als marker für lungenkrebs
US8642347B2 (en) * 2008-01-31 2014-02-04 The Brigham And Women's Hospital, Inc. Urinary CA125 peptides as biomarkers of ovarian cancer
US8476026B2 (en) * 2008-04-01 2013-07-02 The Brigham And Women's Hospital, Inc. Biomarkers of ovarian cancer
WO2010061393A1 (en) * 2008-11-30 2010-06-03 Compugen Ltd. He4 variant nucleotide and amino acid sequences, and methods of use thereof
WO2010102167A1 (en) * 2009-03-05 2010-09-10 Becton, Dickinson And Company Matrix metalloproteinase-7 (mmp-7) monoclonal antibodies and methods for their use in the detection of ovarian cancer
JP2012524521A (ja) 2009-03-06 2012-10-18 トライパス イメージング インコーポレイテッド グリコデリンモノクローナル抗体および卵巣癌の検出におけるその使用のための方法
WO2012027631A2 (en) * 2010-08-26 2012-03-01 University Of Washington Through Its Center For Commercialization Methods for detecting anti-he4 antibodies and methods of diagnosis and/or prognosis of conditions associated with he4-expressing cells
EP2646822B1 (en) * 2010-11-29 2017-11-01 Alere San Diego, Inc. Methods for diagnosis and risk prediction in heart failure
US9822169B2 (en) * 2011-02-17 2017-11-21 Pacific Northwest Diabetes Research Institute Compositions and methods of use for determination of HE4a
WO2012156447A1 (en) * 2011-05-18 2012-11-22 Pronota N.V. New biomarker for the classification of ovarian tumours
US9980982B2 (en) * 2011-06-06 2018-05-29 Women & Infants Hospital Of Rhode Island HE4 based therapy for malignant disease
CA2841880A1 (en) * 2011-07-09 2013-01-17 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2013023994A1 (en) * 2011-08-12 2013-02-21 Pronota N.V. New biomarker for the classification of ovarian tumours
CN103374067A (zh) * 2012-04-26 2013-10-30 清泓生物技术（上海）有限公司 一种在哺乳细胞中制备he4重组蛋白的方法
CN102890083B (zh) * 2012-09-28 2016-08-10 辽宁科骏生物有限公司 化学发光底物溶液和含其的试剂盒及应用其的检测方法
JP2017514815A (ja) * 2014-04-29 2017-06-08 ダウ アグロサイエンシィズ エルエルシー Ｃｒｙ１ｃａ特異的モノクローナル抗体および関連する検出方法
WO2016094409A1 (en) * 2014-12-09 2016-06-16 Villarreal Anna Methods and devices for female health monitoring
CN105866418B (zh) * 2016-06-03 2016-11-09 广州华弘生物科技有限公司 一种乳腺癌三联检诊断试剂盒
CN112979813B (zh) * 2019-12-16 2022-11-08 东莞市朋志生物科技有限公司 一种可特异性结合检测人附睾蛋白4的结合蛋白及其制备方法和应用
CN113045663B (zh) * 2021-04-18 2022-04-01 深圳市国创纳米抗体技术有限公司 一种抗he4的纳米抗体1a8及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7347300A (en) 1999-09-02 2001-03-26 Gene Logic, Inc. Modulation of he4 in inflammatory and renal diseases
AU2002241720A1 (en) 2000-11-08 2002-06-18 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of ovarian cancer
US7270960B2 (en) 2001-08-29 2007-09-18 Pacific Northwest Research Institute Diagnosis of ovarian carcinomas
WO2006089125A2 (en) 2005-02-16 2006-08-24 Dana-Farber Cancer Institute Methods of detecting ovarian cancer
EP2982761B1 (en) * 2006-01-04 2017-10-04 Fujirebio America, Inc. Use of he4 and other biochemical markers for assessment of endometrial and uterine cancers
MX2008009592A (es) * 2006-01-27 2008-09-08 Tripath Imaging Inc Metodos y composiciones para identificar pacientes con una probabilidad incrementada de tener cancer de ovario.

Also Published As

Publication number Publication date
MX2009009450A (es) 2009-12-01
JP2010520768A (ja) 2010-06-17
CA2679696A1 (en) 2008-09-18
AU2008226587A1 (en) 2008-09-18
EP2121761A1 (en) 2009-11-25
KR20100015438A (ko) 2010-02-12
US7846692B2 (en) 2010-12-07
CN101802014A (zh) 2010-08-11
US20110038883A1 (en) 2011-02-17
WO2008112514A1 (en) 2008-09-18
US20080254048A1 (en) 2008-10-16

Similar Documents

Publication Publication Date Title
BRPI0808655A2 (pt) anticorpos monoclonais de he4 e métodos para a sua utilização.
HK1254184A1 (zh) 對抗rgm a蛋白質之單株抗體及其用途
CY2019041I1 (el) Τροποποιημενα αντισωματα εναντι il-23
BRPI0820543A2 (pt) Anticorpo monoclonal capaz de ligar a anexelekto, e uso do mesmo
EP2021373A4 (en) MONOCLONAL ANTIBODY VCAM-1 SPECIFIC
DK2019840T3 (da) Antagonist anti-human CD40 monoklonalt antistof.
NO344963B1 (no) Humanisert antistoff
DK2993186T3 (da) En monoklonal antistof og en fremgangsmåde hertil
NO20076607L (no) TWEAK - bindende antistoff
DK1964852T3 (da) Anti-ilt7-antistof
ZA201000049B (en) Monoclonal antibeta amyloid antibody
BRPI0809677A2 (pt) Anticorpos anti-ige
SI2178921T1 (sl) Monoklonska protitelesa proti glipikan-3
CR10705A (es) Anticuerpos para linfotoxina-alfa
EP1940466A4 (en) ANTI-ADDL MONOCLONAL ANTIBODIES AND THEIR USE
MA28936B1 (fr) Canalisation
DK2292663T3 (da) Antagonistiske human-let-specifikke, humane monoklonale antistoffer
BRPI0814111A2 (pt) Anticorpo monoclonal citotóxico anticâncer
FI20075278A0 (fi) Uudet täysin ihmisperäiset anti-VAP-1 monoklonaaliset vasta-aineet
BRPI0807991A2 (pt) Anticorpos anti-il-23r elaborados.
BRPI0914943A2 (pt) anticorpos de il-6 e sua utilizaÇço
EP2322562A4 (en) MONOCLONAL ANTIBODY AND IMMUNASSAY WITH IT
DK2171060T3 (da) Superagonistisk anti-CD28-antistof
IL200168A0 (en) Monoclonal anti-cxcl13 antibodies
BRPI0817427A2 (pt) Anticorpo anti-bst2

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired